search
Back to results

Decreasing Intakes & Absorption of Phosphorus in Haemodialysis Patients Through Food Choices (DIP HD)

Primary Purpose

Renal Dialysis, Hyperphosphatemia, Dietary Modification

Status
Completed
Phase
Not Applicable
Locations
Ireland
Study Type
Interventional
Intervention
Current Low Phosphorus Diet Prescription
Modified Low Phosphorus Diet Prescription
Sponsored by
University College Cork
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Renal Dialysis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • >18 years
  • Self reported urine output less than 2 cups (400mls) / day
  • On maintenance haemodialysis for > 3 months
  • Phosphate >1.6mmole/L on average of last 3 available routine monthly blood tests

Exclusion Criteria:

  • Hyperkalemia, defined as a predialysis serum K on routine monthly blood test of >6mmoles/l in the month preceding the trial.
  • Parathyroidectomy
  • Corrected serum calcium <2.2 or > 2.6mmol/L or local normal units where ranges varied significantly from 2.2-2.6mmoles/l.
  • Acute concurrent illness, requiring hospitalisation in the 2 weeks prior to recruitment.

Sites / Locations

  • Midland Regional Hospital Tullamore
  • Cavan General Hospital
  • Fiona Byrne
  • St. Vincents University Hospital
  • Mater Misericordia University Hospital
  • Beaumont Hospital
  • Tallaght Hospital
  • Galway University Hospitals
  • University Hospital Limerick
  • Mayo University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Standard Care Arm

Modified Intervention Arm

Arm Description

Patients randomised to the standard care arm will be re educated using the current low phosphorus diet prescription.

Patients randomised to the intervention arm will be educated using a modified low phosphorus diet prescription.

Outcomes

Primary Outcome Measures

Serum Phosphate
Difference in serum phosphate value at 1 month v baseline, in those randomised to the modified diet compared to the difference in serum phosphate value at 1 month v baseline in those randomised to standard care.

Secondary Outcome Measures

Dietary Intake
Between arm difference in dietary phosphate intake (separating phosphate into high & low bioavailability). Between arm difference in dietary fibre intake.
Serum iPTH
Difference in serum iPTH value at 1 month v baseline, in those randomised to the modified diet compared to the difference in serum iPTH value at 1 month v baseline in those randomised to standard care.
Palatability and Subject Acceptance (Tolerability)
Palatability and subject acceptance of modified diet as assessed by 5 point Likert Scale
FGF23 (Exploratory Endpoint)
Within subject change in geometric mean FGF-23 measurement at baseline as compared to the end of the 1 month intervention. Because of evidence that subjects with diabetes handle phosphorus differently we will analyse result for FGF 23 separately in patients with and without diabetes (Muras et al., 2013, Yoda et al., 2012).
Serum Potassium (Safety Endpoints):
Check serum potassium in week 2. Difference in serum potassium value at 1 month v baseline, in those randomised to the modified diet compared to the difference in serum potassium value at 1 month v baseline in those randomised to standard care.

Full Information

First Posted
April 4, 2017
Last Updated
January 15, 2020
Sponsor
University College Cork
Collaborators
Cork University Hospital, Irish Nutrition & Dietetic Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT03146923
Brief Title
Decreasing Intakes & Absorption of Phosphorus in Haemodialysis Patients Through Food Choices
Acronym
DIP HD
Official Title
Decreasing Intakes & Absorption of Phosphorus in Haemodialysis Patients Through Food Choices
Study Type
Interventional

2. Study Status

Record Verification Date
January 2020
Overall Recruitment Status
Completed
Study Start Date
March 6, 2017 (Actual)
Primary Completion Date
June 16, 2017 (Actual)
Study Completion Date
June 16, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University College Cork
Collaborators
Cork University Hospital, Irish Nutrition & Dietetic Institute

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Based on new evidence renal dietitians in Ireland are revising the diet sheet that is used to teach patients about reducing blood phosphate. Changes that renal dietitians plan to make to the dietary phosphorus prescription Inclusion of some nuts and pulses More detailed education re phosphate additives More accurate protein prescription Inclusion of more whole grains Encouraging the use of foods with a low phosphorus to protein ratio The investigators want to test the two diet prescription to find out, which one is better at reducing blood phosphate and which one is more acceptable to patients. The investigators also want to make sure it is safe.
Detailed Description
Background: Chronic Kidney Disease (CKD) afflicts one in twenty Irish citizens who are over age 45 and is a significant risk factor for cardiovascular disease, premature death and significantly impacts healthcare utilisation. As kidney function deteriorates, phosphorus, upregulates counter regulatory hormones (immunoreactive Parathyroid Hormone (iPTH) and Fibroblast Growth Factor 23 (FGF23), the elevated levels of which are maladaptive. Collectively these abnormalities and their complications are referred to as Chronic Kidney Disease, Mineral & Bone Disorder (CKD MBD). Hyperphosphataemia or high blood phosphate levels is associated with increased mortality, in dialysis patients, in the earlier stages of CKD and even in patients with normal renal function. The use of phosphorus restricted diets in combination with oral phosphate binders has become well established in the management of patients with CKD stages 3-5 (including CKD stage 5D). Experts have called for research into the dietary management of phosphate in the CKD population. The current evidence base is weak and in a recent Cochrane systematic review the authors concluded that there was limited low quality evidence to indicate that dietary interventions may positively affect CKD-MBD. In recent years there has been increased focus on dietary phosphorus restriction in the management of CKD-MBD and a number of experts have suggested changes in how we manage dietary phosphorus. Several potential strategies have been suggested and in response the Renal Interest Group (RIG) of the Irish Nutrition & Dietetic Institute (INDI) held a 1 day meeting in Dublin in January 2015 which brought together numerous experts in the field to summarise our current understanding and the recent advances in the field. Following on from this, RIG set up a working group to translate the new knowledge from the advanced study day and from further literature reviews into a modified low phosphate diet sheet. Almost all people who have end stage kidney disease (ESKD) and require dialysis to survive, follow a dietary phosphorus restriction, to control high blood phosphate, with the aim of reducing the risk of cardiovascular disease, fractures and death. Research Hypothesis: The modified low phosphate diet sheet is superior to current treatment in haemodialysis patients Study Objectives Primary Objective: To determine if the modified low phosphorus dietary prescription is superior to current management in reducing serum phosphate levels in HD patients Secondary Objectives To determine if the modified low phosphorus diet is tolerable To determine if the modified low phosphorus diet is safe To determine if the modified low phosphorus diet brings the renal diet closer to healthy eating advice e.g. increased fibre intake.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Renal Dialysis, Hyperphosphatemia, Dietary Modification

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Multicentre Parallel Arm Randomised Controlled Trial
Masking
Participant
Masking Description
As with most education based interventions compared to routine care it is difficult to reliably mask either the subjects or the investigators to the proposed intervention. We will attempt to blind patients referring only to the diets as diet A and diet B and avoiding the use of terminology such as old and new. We will reprint the dietary information for both arms so they do not resemble current illustrated formats.
Allocation
Randomized
Enrollment
74 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Standard Care Arm
Arm Type
Active Comparator
Arm Description
Patients randomised to the standard care arm will be re educated using the current low phosphorus diet prescription.
Arm Title
Modified Intervention Arm
Arm Type
Experimental
Arm Description
Patients randomised to the intervention arm will be educated using a modified low phosphorus diet prescription.
Intervention Type
Other
Intervention Name(s)
Current Low Phosphorus Diet Prescription
Intervention Description
Routine / Standard Care: Routine dietary intervention is currently provided by one-to-one counselling to the subject and his/her relevant family members or carers, by a state registered dietitian regarding a diet which provides <15mg Phosphorus /g Protein (over the day). This is equivalent to approximately 1000mg P / day. This is based on the 'Eating Well with Kidney Disease' dietsheet produced by the Renal Interest Group (RIG) of the Irish Nutrition & Dietetic Institute (INDI) in 2010 and includes following main components: Restricting protein intake to requirements (1-1.2g/kg Ideal Body Weight) Restricting dairy intake (1-1.5 portions per day) Avoiding foods high in phosphate Avoiding foods with phosphate additives
Intervention Type
Other
Intervention Name(s)
Modified Low Phosphorus Diet Prescription
Intervention Description
Modified Low Phosphorus Diet Prescription: The new prescription recommends five changes to current management Introduction of some plant protein in the form of pulses and nuts where the phosphorus is largely bound by phytate Increased focus on avoiding additives Introduction of more whole grains e.g. wholemeal sliced pan/ pasta/rice . Avoiding over-prescription of protein which carries an obligatory phosphorus load. Focus on high protein foods with a low phosphorus to protein ratio
Primary Outcome Measure Information:
Title
Serum Phosphate
Description
Difference in serum phosphate value at 1 month v baseline, in those randomised to the modified diet compared to the difference in serum phosphate value at 1 month v baseline in those randomised to standard care.
Time Frame
1 month
Secondary Outcome Measure Information:
Title
Dietary Intake
Description
Between arm difference in dietary phosphate intake (separating phosphate into high & low bioavailability). Between arm difference in dietary fibre intake.
Time Frame
1 month
Title
Serum iPTH
Description
Difference in serum iPTH value at 1 month v baseline, in those randomised to the modified diet compared to the difference in serum iPTH value at 1 month v baseline in those randomised to standard care.
Time Frame
1 month
Title
Palatability and Subject Acceptance (Tolerability)
Description
Palatability and subject acceptance of modified diet as assessed by 5 point Likert Scale
Time Frame
1 month
Title
FGF23 (Exploratory Endpoint)
Description
Within subject change in geometric mean FGF-23 measurement at baseline as compared to the end of the 1 month intervention. Because of evidence that subjects with diabetes handle phosphorus differently we will analyse result for FGF 23 separately in patients with and without diabetes (Muras et al., 2013, Yoda et al., 2012).
Time Frame
1 month
Title
Serum Potassium (Safety Endpoints):
Description
Check serum potassium in week 2. Difference in serum potassium value at 1 month v baseline, in those randomised to the modified diet compared to the difference in serum potassium value at 1 month v baseline in those randomised to standard care.
Time Frame
1 month

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: >18 years Self reported urine output less than 2 cups (400mls) / day On maintenance haemodialysis for > 3 months Phosphate >1.6mmole/L on average of last 3 available routine monthly blood tests Exclusion Criteria: Hyperkalemia, defined as a predialysis serum K on routine monthly blood test of >6mmoles/l in the month preceding the trial. Parathyroidectomy Corrected serum calcium <2.2 or > 2.6mmol/L or local normal units where ranges varied significantly from 2.2-2.6mmoles/l. Acute concurrent illness, requiring hospitalisation in the 2 weeks prior to recruitment.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Joseph Eustace, MB
Organizational Affiliation
HRB Clinical Research Facility
Official's Role
Principal Investigator
Facility Information:
Facility Name
Midland Regional Hospital Tullamore
City
Tullamore
State/Province
Offaly
ZIP/Postal Code
R35 NY51
Country
Ireland
Facility Name
Cavan General Hospital
City
Cavan
ZIP/Postal Code
H12 K845
Country
Ireland
Facility Name
Fiona Byrne
City
Cork
ZIP/Postal Code
T12DC4A
Country
Ireland
Facility Name
St. Vincents University Hospital
City
Dublin
ZIP/Postal Code
D04 T6F4
Country
Ireland
Facility Name
Mater Misericordia University Hospital
City
Dublin
ZIP/Postal Code
D07 R2WY
Country
Ireland
Facility Name
Beaumont Hospital
City
Dublin
ZIP/Postal Code
D09 C562
Country
Ireland
Facility Name
Tallaght Hospital
City
Dublin
ZIP/Postal Code
D24 NR0A
Country
Ireland
Facility Name
Galway University Hospitals
City
Galway
Country
Ireland
Facility Name
University Hospital Limerick
City
Limerick
ZIP/Postal Code
V94 F858
Country
Ireland
Facility Name
Mayo University Hospital
City
Mayo
ZIP/Postal Code
F23 H529
Country
Ireland

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
Citation
Byrne F, Gillman B, Renal Interest Group INDI, Eustace J. Multicentre Randomized Control Trial of Phosphate Control with a Modified as Compared to Standard Renal Diet TH-OR030. J Am Soc Nephrol 2018;29:8.
Results Reference
background
Links:
URL
https://www.asn-online.org/education/kidneyweek/2018/program-abstract.aspx?controlId=3024392
Description
Link to abstract of oral presentation at the American Society of Nephrology's 2018 Kidney Week

Learn more about this trial

Decreasing Intakes & Absorption of Phosphorus in Haemodialysis Patients Through Food Choices

We'll reach out to this number within 24 hrs